Dineen SP, Pimiento JM. The landmark series: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for treatment of gastric Cancer metastatic to peritoneum. Ann Surg Oncol. 2021;28:4130–7.

Article  PubMed  Google Scholar 

Chia DK, So JB. Recent advances in intra-peritoneal chemotherapy for gastric cancer. J Gastric Cancer. 2020;20:115.

Article  PubMed  PubMed Central  Google Scholar 

Bonnot P-E, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder J-M, Abboud K, Marchal F, Quenet F. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028–40.

Article  CAS  PubMed  Google Scholar 

Brandl A, Prabhu A. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens. J Gastrointest Oncol. 2021;12:S32.

Article  PubMed  PubMed Central  Google Scholar 

Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K. Pharmacokinetic study of Paclitaxel in malignant Ascites from advanced gastric cancer patients. World J Gastroenterology: WJG. 2006;12:1412.

Article  CAS  PubMed Central  Google Scholar 

Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T. Phase II trial of Paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against Paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12:1133–7.

Article  CAS  PubMed  Google Scholar 

Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H, Taguchi T. Phase II study of a combination of S-1 and Paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology. 2008;74:37–41.

Article  CAS  PubMed  Google Scholar 

Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K. Phase I/II study of S-1 combined with Paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer. 2006;95:1642–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K. Nab-paclitaxel versus solvent-based Paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:277–87.

Article  PubMed  Google Scholar 

Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF Inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant Ascites?? Oncologist. 2009;14:1242–51.

Article  CAS  PubMed  Google Scholar 

Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant Ascites formation: initiating events that lead to fluid accumulation. Cancer Res. 1993;53:2631–43.

CAS  PubMed  Google Scholar 

Kipps E, Tan DS, Kaye SB. Meeting the challenge of Ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fushida S, Oyama K, Kinoshita J, Yagi Y, Okamoto K, Tajima H, Ninomiya I, Fujimura T, Ohta T. VEGF is a target molecule for peritoneal metastasis and malignant Ascites in gastric cancer: prognostic significance of VEGF in Ascites and efficacy of anti-VEGF monoclonal antibody, oncotargets and therapy. 2013;1445–51.

Shah MAR, Ramesh K, Ilson DHL, Alissa DOR, D’Adamo, Eileen AT, Tse, Robin LC, Schwartz, Marinela GKK, Schwartz. David P, multicenter phase II study of Irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201–6.

Article  CAS  PubMed  Google Scholar 

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–54.

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.

Article  CAS  PubMed  Google Scholar 

Kang Y-K, Chen L-T, Ryu M-H, Oh D-Y, Oh SC, Chung HC, Lee K-W, Omori T, Shitara K, Sakuramoto S. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234–47.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial. Lancet (London England). 2021;398:27.

Article  CAS  PubMed  Google Scholar 

Suzuki H, Yamada T, Sugaya A, Ueyama S, Yamamoto Y, Moriwaki T, Hyodo I. Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to Ascites burden. Int J Clin Oncol. 2021;26:370–7.

Article  CAS  PubMed  Google Scholar 

Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, Sakamoto J. A new, accurate and conventional five-point method for quantitative evaluation of Ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol. 2005;35:386–90.

Article  PubMed  Google Scholar 

Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622–8.

Article  CAS  PubMed  Google Scholar 

Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant Ascites secondary to gastric cancer. World J Gastroenterology: WJG. 2015;21:10936.

Article  CAS  PubMed Central  Google Scholar 

Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A. Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in Far advanced gastric cancer with peritoneal metastasis (JCOG0106. Jpn J Clin Oncol. 2013;43:972–80.

Article  PubMed  Google Scholar 

Nishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of Paclitaxel in Far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). Gastric Cancer. 2016;19:902–10.

Article  CAS  PubMed  Google Scholar 

Nakajima TE, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H, Nishina T, Sakamoto T, Shitara K, Shinozaki K. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus Paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). Gastric Cancer. 2020;23:677–88.

Article  CAS  PubMed  Google Scholar 

Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K. Phase III trial comparing intraperitoneal and intravenous Paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922–9.

Article  CAS  PubMed  Google Scholar 

Kang SH, Min S-H, Kim JW, Lee E, Park SW, Lee S, Oh HJ, Park YS, Lee YJ, Kim J-W. Safety and efficacy of intraperitoneal Paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2022;29:5084–91.

Article  PubMed  Google Scholar 

Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based Paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep. 2014;32:89–96.

Article  CAS  PubMed  Google Scholar 

Jordan K, Luetkens T, Gog C, Killing B, Arnold D, Hinke A, Stahl M, Freier W, Rüssel J, Atanackovic D. Intraperitoneal bevacizumab for control of malignant Ascites due to advanced-stage Gastrointestinal cancers: a multicentre double-blind, placebo-controlled phase II study–AIO SUP-0108. Eur J Cancer. 2016;63:127–34.

Article  CAS  PubMed